palazestrant
Generic: Palazestrant·Code: OP-1250
palazestrant: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | Phase 3 |
Clinical Trials (1)
A Phase 1b Open-Label Multicenter Study of OP-1250 (Palazestrant) in Combination With the CDK4/6 Inhibitor Ribociclib, With the PI3K Inhibitor Alpelisib, With the mTOR Inhibitor Everolimus, or With CDK4 Inhibitor Atirmociclib in Adult Subjects With Advanced and/or Metastatic ER Positive, HER2 Negative Breast Cancer
Frequently asked questions
Who is developing palazestrant?
palazestrant is being developed by Olema Pharmaceuticals, Inc..
How many clinical trials involve palazestrant?
BioSniper tracks 1 clinical trial involving palazestrant.
Get deeper analysis on palazestrant
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis